Developing a new treatment for triple negative breast cancer using engineered proteins
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy
This study is working on a new treatment for triple negative breast cancer by improving a protein that can better target and block a harmful enzyme, helping to stop the cancer from spreading.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project ID | NIH-11032814 on NIH RePORTER |
What this research studies
This research focuses on creating a more effective treatment for triple negative breast cancer (TNBC) by engineering a human protein called tissue inhibitor of metalloproteinases-2 (TIMP-2). The team aims to enhance the selectivity of TIMP-2 to specifically target MMP-9, an enzyme that plays a crucial role in the progression and spread of TNBC. By improving the binding affinity of TIMP-2 to cancer cells, the researchers hope to block cancer invasion more effectively. The project will involve preclinical testing to evaluate the therapeutic potential of these engineered proteins in various models of TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who may benefit from new treatment options.
Not a fit: Patients with other types of breast cancer or those who do not have breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more targeted and effective therapy for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting MMPs for cancer therapy, but this approach using engineered TIMP-2 is relatively novel.
Where this research is happening
Jacksonville, United States
- Mayo Clinic Jacksonville — Jacksonville, United States (Active)
Researchers
- Principal investigator: Radisky, Evette S — Mayo Clinic Jacksonville
- Study coordinator: Radisky, Evette S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.